FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
Authors:
Open Access
- 2 May 2025
- journal article
- immunotherapy biomarkers
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011648
Abstract
Background: The efficacy of immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) is limited by heterogeneity in individual responses to therapy. The heterogeneous phenotypes and crucial roles of cancer-associated fibroblasts (CAFs) in immunotherapy resistance remain largely unclear. Methods: A specific CAF subset was identified by integrating comprehensive single-cell RNA sequencing, spatial transcriptomics and transcriptome profiling of patients with HCC with different responses to antiprogrammed cell death protein 1 (anti-PD-1) therapy. Mouse orthotopic HCC models and a coculture system were constructed, and cytometry by time-of-flight analysis was performed to investigate the functions and mechanisms of specific CAFs in the immune context of HCC. Results: We identified a distinct flavin-containing monooxygenase 2 (FMO2)+ CAF subset associated with a favorable response to anti-PD-1 therapy and better clinical outcomes. FMO2+ CAFs increase anti-PD-1 treatment efficacy by promoting tertiary lymphoid structure formation and increasing the infiltration of CD8+ T cells and M1-like macrophages through the C-C motif chemokine ligand 19 (CCL19)-C-C motif chemokine receptor 7 axis. Mechanistically, FMO2 promotes nuclear factor kappa B/p65-mediated CCL19 expression by competitively binding to glycogen synthase 1 (GYS1) with praja ring finger ubiquitin ligase 1 (PJA1), thereby suppressing the PJA1-mediated proteasomal degradation of GYS1. CCL19 treatment potentiated the therapeutic efficacy of anti-PD-1 therapy in mouse orthotopic HCC models. A favorable immunotherapy response was observed in patients with HCC with high serum levels of CCL19. Conclusions: We identified a novel FMO2+ CAF subset that serves as a critical regulator of microenvironmental immune properties and a predictive biomarker of the immunotherapy response in patients with HCC. CCL19 in combination with anti-PD-1 therapy may constitute a novel therapeutic strategy for HCC.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LQN25H160024)
- Ministry of Science and Technology of the People’s Republic of China (2024ZD0520400)
- Medical and Health Science and Technology Plan Project of Zhejiang Province (2025699757)
- China National Postdoctoral Program for Innovative Talents (BX20240089)
- National Natural Science Foundation of China (82072666, 82102959, 82172799, 82272774, 82403703, 82473390)
- China Postdoctoral Science Foundation (2024M750544)
This publication has 49 references indexed in Scilit:
- Tertiary Lymphoid Structure in Dental Pulp: The Role in Combating Bacterial InfectionsAdvanced Science, 2024
- CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasisCancer Cell, 2024
- Analysis and Visualization of Single-Cell Sequencing Data with Scanpy and MetaCell: A Tutorial2024
- Smad3 Promotes Cancer‐Associated Fibroblasts Generation via Macrophage–Myofibroblast TransitionAdvanced Science, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma ProgressionHepatology, 2021
- Targeted MIP-3β plasmid nanoparticles induce dendritic cell maturation and inhibit M2 macrophage polarisation to suppress cancer growthBiomaterials, 2020
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerCancer Cell, 2019
- A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune systemCytokine & Growth Factor Reviews, 2013
- Distinct patterns and kinetics of chemokine production regulate dendritic cell functionEuropean Journal of Immunology, 1999